Neuropsychopharmacology of the Trace Amines: Experimental and Clinical Aspects PDF
Preview Neuropsychopharmacology of the Trace Amines: Experimental and Clinical Aspects
Neuropsychopharmacology of the Trace Amines Experimental and Clinical Neuroscience Neuropsycopharmacology of the Trace Amines, edited by R. R. Boulton, P. R. Bieck, L Maitre, and P. Riederer, 79 85 Neurobiology of the Trace Rmines, edited by R. R. Boulton, G.B. Baker, W. G. Dewhurst, and M. Sandler, 7984 Neural Membranes, edited by Grace Y. Sun, Nicolas Bazan, lang-Yen Wu, Giuseppe Porcel/ati, and Rlbert Y. Sun, 7983 NEUROPSYCHOPHARMACOLOGY OF THE TRACE AMINES Experimental and Clinical Aspects Edited by A. A. BOULTON, L. MAITRE, P. R. BlECK, and P. RIEDERER Humana Press · Clifton, New Jersey Library of Congress Cataloging in Publication Data Main entry under title: Neuropsychophannacology of the trace amines. (Experimental and clinical neuroscience) Based on the 2nd Trace Amines Symposium held at Weitenburg Castle May 15-19, 1985. Includes index. l. Biogenic amines--Physiological effect-Congresses. 2. Biogenic amines--Therapeutic use--Congresses. 3. Neuropsychophannacology-Congresses. I. Boulton, A. A. (Alan A.) II. Trace Amines Symposium (2nd: 1985 : Weitenburg Castle) III. Series. [DNLM: l. Amines- congresses. 2. Behavior--drug effects--congresses. 3. Psychophannacology--congresses. QU 60 N4946 1985) QP80l.B66N486 1985 615'.78 85-24904 ISBN-13: 978-1-4612-9397-2 e-ISBN-13: 978-1-4612-50 I 0-4 DOl: 10.1007/978-1-4612-5010-4 ©1985 The Humana Press Inc. Sofkover reprint of the hardcover I st edition 1985 Crescent Manor PO Box 2148 Clifton, NJ 07015 All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise without written permission from the Publisher. PREFACE A probable neurobiological role for the trace amines began to emerge as soon as techniques sufficiently sophisticated to detect them were developed. Techniques for quantitative analyses included radioenzymatic procedures and, more recently, HPlC-EC and auto mated GC-MS. The methods are applied after separation of the sub stances to be analyzed and after their purification by physicochemical procedures that are becoming more and more efficient. The identification and quantitative analysis of minute amounts of trace amines in biological fluids or tissues is in itself a remarkable technological achievement. The enormous task that several teams of research workers have set themselves is to investigate the origin of the trace amines, to understand their metabolism, and to discover whether or not they possess an important biological role. The 2nd Trace Amines Symposium at Weitenburg Castle near Tubingen from the 15th to the 19th May 1985 was held to gain a somewhat clearer insight into the present state of knowledge. Since the first meeting in 1983 our knowledge has increased and interest is deepening. Hence the idea proposed at that first meeting, of organizing similar gather ings at regular intervals, has come to fruition. Covered in the Neuropsychopharmacology section of this book are studiesof the effects of certain trace amines on different forms of be havior, on neurotransmission mediated by . the classical neuro transmitters, on their biosynthesis or on catabolism, on their possible occurrence as a result of alternative metabolic pathways for the amino acids, and in some instances their neuroanatomical distributions. In addition, certain psychotropic and psychotomimetic agents have been shown to influence neurobiochemical and/or behavioral parame ters associated with the trace amines. By contrast, the association of certain of the trace amines with specific receptor sites, compared with the affinity sites for the classical neurotransmitters, are questions that have been touched upon only in a few instances to date. Presented in the Clinical Pharmacology section are analyses of some of the trace amines and their acidic metabolites in certain pathophysiological states and also in healthy volunteers. Also de- v vi Preface scribed are the effects of MAO inhibitors-either of the "classical" or "new" tvpes-on the concentration, elimination, or phVsiological ef fects of the trace amines in humans. It appears to us, therefore, that the combined efforts presentlv be ing made to determine the importance of the trace amines both in experimental biologV and in human clinical pharmacologv promise to open up quite a large field of potential application. In addition, new approaches might well be offered bV which to studV the patho phVsiological bases of certain of the neurological and psvchiatric dis orders. A. A. Boulton, Saskatoon P. R. Bieck, TUbingen L Maitre, 89sel P. Riederer, Vienna ACKNOWLEDGMENTS In 1983 at the conclusion of the successful First Trace Amines Meet ing in Edmonton it was suggested bV our Canadian hosts that a sec ond meeting should be held, preferablv in Europe. The Heads of re search of the Pharma Division of CISA-GEIGY in Sasle and the director of the Medical Department of ClSA-GEIGY in Germanv decided to pro vide some financial help for such a Second Trace Amines Meeting. We wish, therefore, to express our thanks to ClSA-GEIGY for their gener ous and philanthropic support. Financial help from the International Societv of Neurochemistrv is also greatlv appreciated and was most helpful in covering part of the costs of these proceedings. Finallv we thank all the members of the Human Pharmacologv Institute, Ciba Geigv Tubingen, who helped to make this meeting the scientific and social success that it was. CONTRIBUTORS ANTONIN, K. H. • Human Pharmacology Institute, CIBA-GEIGY GmbH, TObingen, Federal Aepublic of Germany AABILLA, S. • Department of Biology, Laboratoires d'Etudes et de Ae cherches Synthelabo, Paris, France BAILEY, B. A.· Psychiatric Aesearch Division, University of Saskatchewan, Saskatoon, Canada BAKEA, G. B. • Neurochemical Aesearch Unit, University of Alberta, Edmonton, Canada BlECK, P. A. • Human Pharmacologll Institute, ClBA-GEIGY GmbH, TObingen, Federal Aepublic of Germany BOULTON, A. A. · Psychiatric Aesearch Division, Saskatchewan Health, University of Saskatchewan, Saskatoon, Canada BAOWN, M. J. • Department of Clinical Pharmacology, Hammersmith Hospital, London, UK COOPER. S. J. • Department of Psychology, University of Birmingham, Birmingham, UK COUTIS, A. T. • Neurochemical Aesearch Unit, University of Alberta, Edmonton, Canada DAVID, J. C. • Laboratoire de Biochimie du Development LA CNAS 256, Universite de Aennes, Paris, France DELISI, L E.· National Institute of Mental Health, Bethesda, Maryland, USA DOWNEA, A. G. H. • University of Waterloo, Department of Biology, Waterloo. Ontario, Canada DUADEN, D. A. • Psychiatric Aesearch Division, Saskatchewan Health, University of Saskatchewan, Saskatoon, Canada DYCK, l. E.· Psychiatric Aesearch Division, University of Saskatchewan, Saskatoon, Canada EDWAADS, D. J. • Department of Pharmacology-Physiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA GILBEAT, D. 8. • Department of Psychology, University of Birmingham, Birmingham, UK vii viII Contributors GOUDIE, A. J. • Psychology Department, University of liverpool, liverpool, UK GAEENSHAW, A. J. • Psychiatric Aesearch Division, University of Saskatchewan, Saskatoon, Canada GUFfAOY, C. • Laboratoires fournier, Centre de Aecherches, Fontaine les Dijon, France HAAAIS, J. • Chemistry Department. Arizona State University, Tempe, Arizona, USA HETEY, l. • Institute of Pharmacology and Toxicology, Humboldt Uni versity, Berlin, Federal Aepublic of Germany JUOAIO, A. V. • Psychiatric Aesearch Division, Saskatchewan Health, University of Saskatchewan, Saskatoon, Canada KAAOUM, F. • Neuropsychiatry Branch, NIMH Saint Ellzabeths Hospi tal, Washington, DC, USA KIENZL, E. • Ludwig-Boltzmann Institut fOr Klinlsche Neurobiologie, Krankenhaus Wien-Lainz, Wien, Austria KINEMUCHI, H. · Department of Pharmacology, Showa University, Tokyo, Japan KISAAA, K. • Department of Pharmacology, Tohuko College of Phar macy, Japan LANGEA, S. Z. • Department of Biology, Laboratoires d'Etudes et de Aecherches Synthelabo, Paris, France LAASON, A. A. • Department of Veterinary Biology, College of Veteri nary Medicine, Saint-Paul, Minnesota, USA LOCOCK, A. A. • Neurochemical Aesearch Unit, University of Alberta, Edmonton, Canada MAITAE, l.. Aesearch Department, CIBA-GEIGY AG, Basel, Switzerland MCQUADE, P. • Douglas Hospital Aesearch Centre, Verdun, Quebec, Canada MOISES, H. W. • Central Institute of Mental Health, Mannheim, fed eral Aepublic of Germany MOSNAIM, A. D. • Chicago Medical School, North Chicago Veteran's Administration Medical Center and Loyola University, North Chicago, Illinois, USA MUAPHY, D. l. • Clinical Neuropharmacology Branch, NIMH, NIH Clinical Center, Bethesda, Maryland, USA NAZAAALI, A. J. • Neurochemical Aesearch Unit, University of Alberta, Edmonton, Canada Contributors Ix OAELAND, l.. Department of Pharmacology, University of Gothenburg, Gothenburg, Sweden OATMANN, A.· Aesearch Department, CIBA-GEIGY AG, Basel, Switzerland OSBOANE, N. N. • Nuffield laboratory of Ophthalmology, University of Oxford, Oxford, UK PHILIPS, S. A. • Psychiatric Aesearch Division. Saskatchewan HeQlth, University of Saskatchewan, Saskatoon, Canada AEINHAAD, J. F.· The Wellcome Aesearch laboratories, North California, California, USA AEYNOlDS, G. P.· Department of Pathology, University of Nottingham, Nottingham, UK AIEDEAEA, P. • ludwig-Boltzmann Institut fOr klinische Neurobiologie, Krankenhaus Wien-lainz, Wien, Austria AOMMELSPACHEA, H. • Department of Neuropsychopharmacology, Frele Universltat Berlin, Berlin, Federal Aepublic of Germany SANDLER. M. • Bernhard Baron Memorial Aesearch laboratoires. Queen Charlotte's Maternity Hospital, london, UK STULA-DElINI. A. • Aesearch Department, CIBA-GEIGY AG, Basel. Switzerland TADANO, T. • Department of Pharmacology, Tohuko College of Phar macy, Japan WAlDMEIEA, P. C. • Aesearch Department, CIBA-GEIGY AG, Basel, Switzerland WEll-FUGAZZA, J. • Unite de Neurophysiologie Pharmacologique, Paris, France WEINEA, N. • Physiologisch-Chemlsches Institut, Philipps Universitat, Marburg/lahn, Federal Aepublic of Germany WOlLMANN, H. • Human Pharmacology Institute, (lBA-GEIGY GmbH, TObingen, Federal Aepublic of Germany YEUNG, J. M. • Neurochemical Aesearch Unit, University of Alberta, Edmonton, Canada YU, P. H. • Psychiatric Aesearch Division. Saskatchewan Health, Uni versity of Saskatchewan, Saskatoon, Canada CONTENTS Preface. .. . .... . ........... . . ..... . .. ..... . . ....... ... ....... v INTRODUOION The Trace Amines: Aecent Overview and Future Pointers. . . . . . . . . . . 3. A. A. Boulton NEUROPSYCHOPHARMACOlOGY Invited Communications Cerebral 2-Phenvlethvlamine Concentrations and Turnover Not Influenced bV Various Pharmacological Treatments in Aats .. . . . . 15 P. C. Waldmeier, A. M. Buchle, and J. Lauber Pharmacological Profile of Beta-Phenvlethvlamine on Dopaminergic and Noradrenergic Neurotransmission in Aat Cerebral Slices: Comparison with Amphetamine and Other Trace Amines. . . . . . . . 27 S. Z. langer, S. Arbilla, R. Niddam, S. Benkirane, and P. Baud Further Investigation of the Metabolism of Two Trace Amines, Beta Phenvlethvlamine and p-Tvramine bV Aat Aorta Semicarbazide- Sensitive Amine Oxidase. . . . . . . . . . . . . . . . . . . . . . . . . 3. 9. . . . . . . . . C. Guffroy, T. Boucher, and M. Strolin Benedetti In Vivo Discriminative Stimulus (CUE) Properties in Aats of Beta- Phenvlethvlamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 .1 . . . . . . . . . A. J. Goudie and D. Reid Effect of Psychoactive Drugs on Behavior Induced bV 2- Phenvlethvlamine in Aats . . . . . . . . . . . . . . . . . . . . . . . . . 6. 3 . . . . . . . . R. Ortmann, M. Schaub, and P. C. Waldmeier Potentiation of the Biochemical Effects of Beta-Phenvlethvlamine and Tryptamine bV Deuterium Substitution. . . . . . . . . . . . . . . . . . 7. 5. . . . . l E. Dyck, B. A. Davis, D. A. Durden, and A. A. Boulton Possible Pathways for Some Trace Amine-Containing Neurons ... . . . . 87 A. V. Juorlo, A. J. Greel)~haw, and A. A. Boulton [3H1Trvptamine Aeceptors in Aat Brain. . . . . . . . . . . . . . . . . . ... . . 101 . . . . P. l Wood, II Martin, and C. A. Altar xl
Description:The list of books you might like
